SCHEMBL1363358

SCHEMBL1363358

O=C(O)C=Cc1cccc(-c2ccnc3[nH]cc(C(=O)c4ccccc4F)c23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM2 Q9P1W9 7/20 0.46
LRRK2 Q5S007 6/20 0.39
DNTT P04053 1/20 0.39
EGFR P00533 3/20 0.38
DCLK1 O15075 1/20 0.37
DYRK3 O43781 1/20 0.37
ROCK2 O75116 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
ABL1 P00519 1/20 0.37
NTRK1 P04629 1/20 0.37
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37
CDK1 P06493 1/20 0.37
CSF1R P07333 1/20 0.37
LYN P07948 1/20 0.37
SRC P12931 1/20 0.37
MARK3 P27448 1/20 0.37
AXL P30530 1/20 0.37
FLT4 P35916 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL857089 1.00 PIM2 (0.46) PIM2LRRK2DNTTEGFRDCLK1
SCHEMBL857008 0.91 PIM2 (0.44) PIM2LRRK2EGFRROCK2MAP4K4
SCHEMBL1364814 0.91 PIM2 (0.44) PIM2LRRK2EGFRROCK2MAP4K4
SCHEMBL1362095 0.90 PIM2 (0.47) PIM2LRRK2BTK
SCHEMBL856856 0.90 PIM2 (0.47) PIM2LRRK2BTK
SCHEMBL1363631 0.86 PIM2 (0.44) PIM2LRRK2EGFRROCK2MAP4K4
SCHEMBL858333 0.86 PIM2 (0.44) PIM2LRRK2EGFRROCK2MAP4K4
SCHEMBL857900 0.86 PIM2 (0.45) PIM2LRRK2EGFRFYNBTK
SCHEMBL1364351 0.86 PIM2 (0.45) PIM2LRRK2EGFRFYNBTK
SCHEMBL1362011 0.83 PIM2 (0.46) PIM2LRRK2EGFRDYRK3ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067434-B2 Compounds and methods for development of Ret modulators PLEXXIKON INC. (US) 2011-11-29 US claimed
US-20100324065-A1 Compounds and methods for development of Ret Modulators PLEXXIKON INC 2010-12-23 US claimed
US-7504509-B2 Compounds and methods for development of Ret modulators PLEXXIKON, INC. (US) 2009-03-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324065-A1 Compounds and methods for development of Ret Modulators RET, GFRA3, GFRA1 PIM2 2832/4885LRRK2 96/4885DNTT 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.